Why Cognition Therapeutics, Inc.’s (CGTX) Stock Is Up 7.54%
As of Thursday, August 06, Cognition Therapeutics, Inc.’s CGTX share price has surged by 7.54%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: Cognition Therapeutics, Inc. (CGTX)
Cognition Therapeutics, Inc. CGTX
$1.01
-0.02
-1.94%
September 8, 2026 4:00:00 PM
EST
Volume: 261,198
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer’s disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Commentary & Analysis
Why Cognition Therapeutics, Inc.’s (CGTX) Stock Is Up 6.48%
As of Wednesday, August 05, Cognition Therapeutics, Inc.’s CGTX share price has surged by 6.48%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Cognition Therapeutics, Inc.’s (CGTX) Stock Is Up 6.57%
As of Tuesday, August 04, Cognition Therapeutics, Inc.’s CGTX share price has surged by 6.57%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Cognition Therapeutics, Inc.’s (CGTX) Stock Is Down 6.43%
As of Tuesday, July 28, Cognition Therapeutics, Inc.’s CGTX share price has dipped by 6.43%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Cognition Therapeutics, Inc.’s (CGTX) Stock Is Up 5.40%
As of Tuesday, July 21, Cognition Therapeutics, Inc.’s CGTX share price has surged by 5.40%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | CGTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $97.9 | $672.4 | 21% |
|
| Shares Out (Mil) | 90.6 | 43.4 | 60% |
|
| Institutional Ownership | 90.9% | 84.2% | 59% |
|
| Float (Mil) | 87.4 | 46.2 | 58% |
|
| Beta | 1.78 | 0.73 | 88% |
|
| Avg Daily Volume (000s) | 340 | 291 | 54% |
|
| Price Change (52-week) |
(60.2%) | 69.2% | 11% |
|
| Growth | CGTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (24.7%) | (1.5%) | 17% |
|
| EPS (5yr) | 57.7% | 15.1% | 95 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (48.7%) | (15.0%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 2 | |
| Current EPS | ($0.067) | ($0.297) | ($0.220) | |
| Month Ago EPS | ($0.070) | ($0.345) | ($0.220) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.073) | ($0.323) | ($0.277) | |
| Year/Year Chg | 55.8% | (8.0%) | 26.9% | |
| Financials | CGTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($17) | ($11) | 25% |
|
| EPS (TTM) | ($0.194) | ($0.700) | 34% |
|
| Operating Cash Flow (TTM) (Mil) | ($18) | ($7) | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $6 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 14% |
|
| Enterprise Value (Q1) (Mil) | $66 | $525 | 18% |
|
| Valuation | CGTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.94 | 2.80 | 64% |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CGTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.8% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (57.3%) | (24.6%) | 10% |
|
| ROE | (83.8%) | (21.4%) | 11% |
|
| Liabilities to Assets | 15.1% | 32.3% | 9% |
|
| F-Score | 2 | 3 | 7% |
|
Cognition Therapeutics, Inc. did not pass any screens on 9/4/2026.
